Organization (Industry)
MIRUM PHARMACEUTICALS, INC.
ClinicalTrials.gov lists MIRUM PHARMACEUTICALS, INC. as lead sponsor of 39 trials. It has 49 active development programs and 6 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 5 registered with a 2026 start date. The dashed outline is the pace from the 5 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 2.2 trial starts a year over the five years to September, under the 5 a year the method needs. 1 trial is registered to start in 2027 or later.
This page covers MIRUM PHARMACEUTICALS, INC.: 39 lead-sponsored trials and 2 legal-entity registrations.
Related companies are recorded in the same corporate group by GLEIF, ROR or a curator but are not grouped here; they are listed below with their own counts and are not included in the figures above.
Disease areas (36)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Cholestasis | 22 |
| Alagille Syndrome | 11 |
| Heart Defects, Congenital | 11 |
| Pruritus | 8 |
| Cholangitis | 4 |
Showing 5 of 36 disease areas.
Trials by start year as sponsor or collaborator (15)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 5 |
| 2025 | 4 |
| 2024 | 1 |
| 2023 | 1 |
| 2021 | 5 |
| 2020 | 4 |
| 2019 | 1 |
| 2018 | 1 |
| 2017 | 1 |
| 2016 | 1 |
Showing 10 of 15 years.
Prediction, not a registry value: median of 33 months from start to primary completion across 7 trials still running at the 2026-10-09 snapshot; registered median of 33 months across 24 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (49)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Brelovitug 300 mg | Hepatitis D | Phase 3 | 3 |
| Brelovitug 900 mg | Hepatitis D | Phase 3 | 2 |
| Delayed Treatment with Brelovitug 300mg | Hepatitis D | Phase 3 | 2 |
| Maralixibat | Biliary Atresia | Phase 3 | 2 |
| Maralixibat | Pruritus | Phase 3 | 2 |
Showing 5 of 49 active programs.
Approved assets (6)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Livmarli Oral Product | 1 |
| Maralixibat | 10 |
| Cholic Acid | 3 |
| Bulevirtide | 1 |
| LUM001 | 10 |
Showing 5 of 6 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 60% hit target (n=15) | 21% on time (n=14) |
Journals published in (15)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Journal of pediatric gastroenterology and nutrition | 3 |
| Genetics in medicine : official journal of the American College of Medical Genetics | 2 |
| Hepatology communications | 2 |
| BMC pharmacology & toxicology | 1 |
| European journal of drug metabolism and pharmacokinetics | 1 |
Showing 5 of 15 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 4 | 4 | 2025-05-13 |
SEC-reported annual financials (8)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | 521,312,000 | -23,363,000 | 186,178,000 |
| 2024 | 336,888,000 | -87,942,000 | 140,630,000 |
| 2023 | 186,374,000 | -163,415,000 | 102,609,000 |
| 2022 | 77,062,000 | -135,665,000 | 106,842,000 |
| 2021 | 19,138,000 | -83,988,000 | 131,428,000 |
| 2020 | 0 | -103,270,000 | 81,605,000 |
| 2019 | not reported | -52,553,000 | 42,991,000 |
| 2018 | not reported | not reported | not reported |
Financing and grant events (30)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2026-05-15 | Debt financing | 671 | Sec extracted |
| 2026-05-12 | Debt financing | not disclosed | Sec extracted |
| 2026-02-25 | Follow-on offering | 935,707,411 | Edgar offerings |
| 2026-01-23 | Private placement | not disclosed | Sec extracted |
| 2026-01-23 | Private placement | 68,480,000 | Form d |
Showing 5 of 30 events.
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| NAI | 3 |
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | not disclosed | not disclosed |
Organization relationships (23)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Childhood Liver Disease Research and Education Network | Co sponsors trial with | 2 |
| Montefiore Health System | Co sponsors trial with | 1 |
| Ara Parseghian Medical Research Fund | Co sponsors trial with | 1 |
| Government of the United States of America | Co sponsors trial with | 1 |
| Cincinnati Children's Hospital Medical Center | Co sponsors trial with | 1 |
Showing 5 of 23 relationships.
Latest dated events (86)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2027-01-15 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2027 H1 | PDUFA decision date | Regulatory decision dates extracted from SEC filings |
| 2027 Q1 | PDUFA decision date | Regulatory decision dates extracted from SEC filings |
| 2026-05-29 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-05-15 | Debt facility | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
Showing 5 of 86 events.
Biomarker capability evidence (93)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ABCB11 | Trial sponsor | Named in trial inclusion criteria |
| ABCB11 | Trial sponsor | Named in trial inclusion criteria |
| ABCB11 | Trial sponsor | Named in trial inclusion criteria |
| ABCB11 | Trial collaborator | Named in trial inclusion criteria |
| ABCB4 | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 93 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, fda warning letters, fda untitled letters, fda recalls, fda import refusals, manufacturing and distribution sites, clia clinical laboratory certificates, and biomarkers this organization publishes on.